KMT2Acoproteins诱导了对向治疗的表观遗传抵抗
bioRxiv : the preprint server for biology
|January 18, 2024
概括
KMT2Acoproteins通过破坏基因表达来驱动白血病,其水平决定了ALL或AML程序. 治疗可以诱导血统切换,通过ENL标记的表观遗传变化导致耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 涉及KMT2A的染色体转位会产生致癌的融合蛋白.
- 这些型蛋白质破坏了正常的基因表达调节,特别是在发育过程中.
- KMT2A的重组与各种白血病有关.
研究的目的:
- 在KMT2A重新排列的白血病样本中对coprotein目标部位进行分析.
- 了解coprotein基因组丰富的可变性和动态调节.
- 调查治疗诱导的血统切换和治疗抵抗背后的机制.
主要方法:
- 在36个KMT2A重排列的白血病样本中对coprotein目标部位的基因组分析.
- 样本的分析与淋巴细胞到骨髓细胞血统切换.
- 研究与基因表达程序 (ALL,AML,GMP) 相关的coprotein水平和结合模式.
- 在耐治疗样本中评估ENL辅因子持久性.
主要成果:
- coprotein基因组丰富是高度可变和动态调节的.
- 高水平的上蛋白激活了ALL (亲B细胞基因) 或AML (造血干细胞基因) 程序.
- 血统切换样本显示蛋白水平降低和GMP基因的激活.
- 在一个案例中,尽管在revumenib治疗期间无法检测到coprotein和menin水平,但ENL在目标位点上持续存在.
结论:
- KMT2A基蛋白可以通过动态染色体结合促进血统切换.
- 由ENL标记的表观遗传病变可能导致对向疗法的耐药性.
- 了解这些机制对于开发有效的白血病治疗至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.6K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
